key: cord-0866310-5fvqukyl
authors: Flores-Gonzalez, Ramon E; Hernandez, Jeffrey; Tornes, Leticia; Rammohan, Kottil; Delgado, Silvia
title: Development of SARS-CoV-2 IgM and IgG antibodies in a Relapsing Multiple Sclerosis patient on Ofatumumab
date: 2021-01-19
journal: Mult Scler Relat Disord
DOI: 10.1016/j.msard.2021.102777
sha: c353ceeb3bf6f1b131d48d53e6468f5d6db92579
doc_id: 866310
cord_uid: 5fvqukyl

We report the case of a MS patient on subcutaneous ofatumumab who became infected with SARS-CoV-2 and remained asymptomatic while developing antiviral IgM and IgG antibodies. The patient was B-cell depleted with normal serum immunoglobulin levels. Anti-SARS-CoV-2 IgG antibodies remained positive three months after the initial infection. These findings suggest that a MS patient treated with ofatumumab may be able to mount an effective humoral response to SARS-CoV-2 infection and probably to COVID-19 vaccines as well. Further research will be necessary to evaluate the humoral response of MS patients on ofatumumab to SARS-CoV-2 infection and COVID-19 vaccines.

The current COVID-19 global pandemic has raised important questions regarding the immune response to viral infection of MS patients treated with immunomodulating drugs, particularly those on highly effective anti-CD20 monoclonal antibodies like ocrelizumab and ofatumumab 1 . Another point of great interest is how effectively patients treated with these drugs would respond to anti-SARS-CoV-2 vaccinations.

We report a patient with relapsing MS (RMS) on subcutaneous ofatumumab therapy for 42 months who had laboratory-confirmed SARS-CoV-2 infection and developed antiviral IgM and IgG antibodies. The patient had contact with a family member who tested positive for COVID-19 infection, which prompted her to get tested. Pharyngeal swab testing for the SARS-CoV-2 viral RNA by PCR and serological testing were performed. Viral RNA was identified from the pharyngeal swab, and SARS-CoV-2 antibodies (IgM and IgG) to the viral spike protein were detected using the COVID-19 IgG/IgM Rapid Test Cassette, Whole Blood/Serum/Plasma, Healgen®. 4 The patient remained asymptomatic. Her ofatumumab injection was held until she tested negative on repeat COVID-19 swab testing two weeks after her initial positive test. The patient resumed ofatumumab injections and continued asymptomatic. Serological testing was repeated three months after the first antibody test. Anti-SARS-CoV-2 IgG to the spike protein was reported positive (Quest Laboratories, using the VITROS Anti-SARS-CoV-2 Total Reagent Pack and Calibrator, Ortho-Clinical Diagnostics, Inc.). 4 She had been fully B-cell depleted in blood, and her serum IgG and IgM levels remained within normal limits. (Table 1 ).

Ofatumumab is a fully human anti-CD20 monoclonal antibody that selectively depletes B cells. It is recently approved by the FDA for the treatment of RMS. In phase 3 clinical trials, ofatumumab administered subcutaneously was highly effective to reduce clinical and MRI disease activity in RMS patients. 2, 5 Serial serum IgM and IgG analysis from ASCLEPIOS I/II participants showed that IgG levels were decreased from baseline until week 36 and recovered up to baseline level at week 72 in ofatumumab treated patients. IgM levels were reduced from baseline but remained within the reference range for most of the patients in the ofatumumab group. 6 Our MS patient was treated with ofatumumab for 42 months and was fully B-cell depleted with normal serum IgG and IgM levels when infected with the SARS-CoV-2 virus. She remained clinically asymptomatic. She mounted a successful humoral response to the virus with IgM and IgG antibodies, and anti-SARS-CoV-2 IgG remained positive three months after her initial positive serological testing.

The humoral response to selected vaccines of RMS patients treated with IV ocrelizumab, another anti-CD20 monoclonal antibody, was evaluated in a phase 3b trial (VELOCE). 7 This study showed that patients receiving ocrelizumab mounted a diminished humoral response to these vaccines compared with the control group (no treatment or IFN-β). It was recently reported that two ocrelizumab-treated MS patients experienced symptomatic COVID-19 infection but did not develop SARS-CoV-2 antibodies several weeks post-infection. 8 Another MS patient on ocrelizumab with mild COVID-19 and mildly decreased IgG level developed anti-SARS-CoV-2 IgA several weeks after infection but no specific IgG response. 9 Additionally, another patient on ocrelizumab with low IgG and IgM levels was SARS-CoV-2 IgG negative two months after COVID-19 infection. These findings have raised the concern of an attenuated humoral response in ocrelizumab-treated patients with hypogammaglobulinemia. 10 The findings from this patient suggest the possibility that patients on subcutaneous ofatumumab may be able to mount an effective humoral response to SARS-CoV-2 infection and probably COVID-19 vaccines. To date, there have been no published reports of patients on ofatumumab developing anti-SARS-CoV-2 antibodies. The humoral response of ofatumumab-treated patients to COVID-19 infection or vaccination is an important area that warrants further investigation.

COVID-19 and MS disease modifying therapies

for the ASCLEPIOS I and ASCLEPIOS II trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis

An open-label, single arm, multi-center extension study evaluating longterm safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis. NCT03650114. Sponsored by Novartis Pharmaceuticals

19-emergency-useauthorizations-medical-devices/eua-authorized-serology-test-performance. Current as of

Ofatumumab-A potential Subcutaneous B-cell therapy for relapsing Multiple Sclerosis

Effect of Ofatumumab on Serum Immunoglobulin levels and infection risk in relapsing Multiple Sclerosis patients from the phase 3 ASCLEPIOS I and II trials. Poster LB82. 6 th Congress of the European Academy of Neurology

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study

Negative SARS-CoV-2 antibody testing following COVID-19 infection in two MS patients treated with ocrelizumab

Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report

Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia